Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica’s U.S. Feline, Canine and Rabies Vaccines Portfolio

(08.10.2016) Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business; subject to FTC approval and closing of BI/Sanofi asset swap

Elanco Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for million, including the estimated cost of acquired inventory.

The deal will diversify Elanco’s U.S. companion animal portfolio by complementing its offerings for dogs and cats.

Joining Elanco’s U.S. portfolio – which currently includes parasiticides, pain and dermatology medicines – will be routinely administered vaccines for bordetella, Lyme disease, rabies and parvovirus, among others. Also included in the agreement are several pipeline assets.

The Fort Dodge, Iowa-based facility brings capacity to manufacture the acquired products as well as R&D and testing capabilities, including an on-site veterinary research center and lab space.

“We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives,” said Jeff Simmons, president, Elanco Animal Health. “With a growing portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet caregivers to do just that.”

The acquisition is anticipated to close by early 2017, subject to approval by the Federal Trade Commission and also subject to antitrust approval and closing of Boehringer Ingelheim’s asset swap transaction with Sanofi.

The sale of BIVI’s U.S. pet vaccines business and Fort Dodge manufacturing site is a required step toward the acquisition of Merial by Boehringer Ingelheim.

The current vaccine portfolio to be acquired has experienced revenue growth over the past three years, and Lilly expects the acquisition to be accretive to GAAP earnings in 2019 and to non-GAAP earnings in 2018.

John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer, said that the planned acquisition of BIVI’s U.S. feline, canine and rabies vaccines portfolio reaffirms Lilly’s confidence in Elanco’s growth potential.

“As a result of the acquisition, Elanco will bring greater value to customers by providing a suite of options for preventing common diseases in companion animals,” said Lechleiter. “Coupled with our robust food animal portfolio, this addition further strengthens Elanco’s position in the global animal health business.”

Jefferies LLC is acting as the exclusive financial advisor and Paul Hastings LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as legal advisors to Elanco and Lilly in this transaction.

Products included within the acquisition:

Canine:

Duramune®
Duramune® Max 5/4L
Duramune® Max 5
Duramune® Max 5-Cvk/4L
Duramune® Max 5-Cvk
Duramune® Max Pv
Duramune® CV-K
Duramune® Max PC
Duramune® Adult 3
LeptoVax® 4
LeptoVax® 4/C
Bronchi-Shield®
Bronchi-Shield® Oral
Bronchi-Shield® III
Duramune Lyme®
Duramune Lyme®
Duramune Lyme® + LeptoVax® 4
Duramune Lyme® + Max 5/4L
Duramune Lyme® + Max5-CvK/4L
Duramune Lyme® + Max5-CvK
Duramune Lyme® + Leptovax® 4/C
ULTRATM Duramune®
ULTRATM Duramune® DAP+4L
ULTRATM Duramune ® DAP
ULTRA TMDuramune ® 4L
ULTRATM Duramune ® DAP+C4L
ULTRATM Duramune ® DAP+C
ULTRA TM Duramune Lyme®

Feline:

Fel-O-Vax®
Fel-O-Vax® Lv-K® IV + CaliciVax®
Fel-O-Vax Lv-K® III + CaliciVax®
Fel-O-Vax® Lv-K®
Fel-O-Vax® IV + CaliciVax®
Fel-O-Vax® PCT + CaliciVax®
Fel-O-Vax® Lv-K + FIV®
Fel-O-Vax® FIV®
CaliciVax®
ULTRATM Fel-O-Vax®
ULTRATM Fel-O-Vax® FVRCP+FeLV
ULTRATM Fel-O-Vax® FVRCP
ULTRATM Fel-O-Vax® FeLV
ULTRATM Fel-O-Vax® Dual FCV
ULTRATM Hybrid FVRCP
Fel-O-Guard®
Fel-O-Guard® Plus 3
Fel-O-Guard® Plus 3 + Lv-K
Fel-O-Guard® Plus 4
Fel-O-Guard® Plus 4 + Lv-K
Rabies
Rabvac®
Rabvac®3
Rabvac® 1




Weitere Meldungen

CCRP, CERP and Friends Reunion

Das war die "CCRP, CERP and Friends Reunion" in Charleston

Zehn wissenschaftliche Daten verpackt in innovative und lustige Präsentationen, köstliche, amerikanische Speisen, erfrischende Getränke und geschwungene Tanzbeine – die erste VAHL-Reunion in Charleston zur Feier der Kooperation mit der University of Tennessee war ein riesiger Erfolg
Weiterlesen

Europäischer Fuchsbandwurm; Bildquelle: Shutterstock

Europäischer Fuchsbandwurm auf dem Vormarsch

Studie weist auf Verbreitung in den USA hin: die Alveoläre Echinokokkose (AE) ist eine schwere Parasiten-Erkrankung, die durch den Fuchsbandwurm ausgelöst wird und unbehandelt tödlich verläuft
Weiterlesen

Dr Muhammad Hasan Mahrous; Bildquelle: WSAVA

WSAVA Future Leader Award for Dr Muhammad Hasan Mahrous

Dr Muhammad Hasan Mahrous, an Egyptian veterinarian who qualified in 2018 and works at a veterinary clinic in Dubai
Weiterlesen

Skelett und Schädel (Vergrößerung) eines der seltenen Funde von Tsoabichi greenriverensis, einem frühen Kaiman, aus den rund 52 Millionen Jahre alten Gesteinen der Green-River-Formation in Wyoming, USA.; Bildquelle: A. Fatz, T. Massonne, G. Darlim

Forscher der Universität Tübingen ordnen seltene Fossilfunde in die Evolutionsgeschichte der Krokodile ein

Zwei rund 52 Millionen Jahre alte Fossilfunde aus der Green-River-Formation im US-amerikanischen Wyoming konnten in einer neuen Studie in die Evolutionsgeschichte der Krokodile eingeordnet werden
Weiterlesen

Science

Forscher lösen Rätsel: Cyanobakterium löst Vacuolar Myelinopathy (VM) aus

Im Süden der USA sterben seit den 1990er Jahren Weißkopfseeadler, aber auch andere Vögel sowie Reptilien und Fische an einer mysteriösen neurodegenerativen Krankheit
Weiterlesen

Minnesota Urolith Center (MUC) Team

Double Celebration as Minnesota Urolith Center Analyzes 1.5 Millionth Stone and Marks 40 Years of Service

Support from Hill’s Pet Nutrition sustains vital service for veterinarians worldwide
Weiterlesen

Dr Elizabeth Boudreau; Bildquelle: WSAVA

Canine Cancer and Neurology Specialist to Receive the 2021 WSAVA Future Leader Award

Dr Elizabeth Boudreau, Assistant Professor of Small Animal Neurology at Texas A&M University, USA, is to receive the 2021 WSAVA Future Leader Award in recognition of her contribution to research and her role as an educator
Weiterlesen

Dr Stephen DiBartola; Bildquelle: WSAVA

Companion Animal Clinician, Educator and Researcher to receive the 2019 WSAVA Scientific Achievement Award

Dr Stephen DiBartola, Professor Emeritus at the Ohio State University, USA, is to receive the 2019 WSAVA Award for Scientific Achievement in recognition of his global contribution to small animal clinical practice, particularly in the areas of nephrology and acid-base disorders
Weiterlesen


Wissenschaft


Universitäten


Neuerscheinungen